{"id":"and017-capsules-qw","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"null","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, AND017 capsules QW also has a mild diuretic effect, which can help reduce blood pressure.","oneSentence":"AND017 capsules QW is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:27.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AND017 capsules QW","genericName":"AND017 capsules QW","companyName":"Kind Pharmaceuticals LLC","companyId":"kind-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AND017 capsules are a small molecule treatment for Renal Anemia in patients with chronic kidney disease on dialysis. They are administered once a week (QW) as part of a clinical study comparing their efficacy and safety to other treatments, including epoetin alfa, darbepoetin alfa, and Mircera.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}